ANXA1 and cancer: Furthermore, a First-In-Human study evaluating the safety and tolerability of MDX-124 alone and in combination with anti-cancer therapies has recently been initiated in patients with locally advanced, unresectable or metastatic solid malignancies known to overexpress ANXA1.